CAB+RPV LA is versatile, preferred in treatment-naive patients

AJMC news story

The combination of long-acting cabotegravir with rilpivirine (CAB+RPV LA) has been used as a method of treating HIV. The injections can be received either monthly or every other month, potentially making them an appealing alternative to daily pills due to its persistent efficacy. In posters presented during CROI 2026, researchers evaluated whether treatment-naive patients prefer the CAB+RPV LA treatment to daily pills (VOLITION study) and how effective it was in patients with viral loads of 50 copies/mL or more compared with patients with less than 50 copies/mL (OPERA study).

Read the full news story here.View all AJMC reports from CROI 2026